February 4, 2016
Another new treatment for Hepatitis C has been approved in Canada. This medication is geared to Genotype 1, 3 and 4 in adults. Zepatier is currently not covered by Ontario Drug Benefit Program.
To read the article: www.newswire.ca/news-releases/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-with-genotype-1-3-or-4-infection-following-priority-review-567492691.html
Please take to Keri or Kelsey for more information on this treatment.